Indraprastha Medical Corporation Limited
INDRAMEDCO · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹512.08.
Piotroski F-score 6/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%27.5%
- ✓Low debt (D/E < 0.5)0.05x
- ✓Positive free cash flow
- ✕Revenue growth > 10%9%
- ✓Earnings growing2%
- ✓Net margin ≥ 10%12.4%
- ✓Current ratio > 1.52.46
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✕Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 10.55
- ✕Piotroski ≥ 76/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Analyst views
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (27.5%).
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 10.55.
Weaknesses
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Trading in our value buy zone versus sector peers.
- •Well off its 52-week high — possible mean-reversion.
- •Trades ~68% below our estimated fair value.
About Indraprastha Medical Corporation Limited
Indraprastha Medical Corporation Limited provides hospital services in India. The company offers services primarily in the areas of sugar, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic clinic, dermatology, dietetics and clinical nutrition, vascular and endovascular surgery, endocrinology, ENT, fetal medicine, general and laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF,
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.